Events 2022 2021 2020 Maryland Life Sciences Bio Innovation Conference October 3-4, 2022, Bethesda Country ClubOctober 3, 10:00 a.m. ET-Dr. Milos Miljkovic, Chief Medical Officer, participates in the Expanding the Boundaries of Cell and Gene Therapy session. Dr. Miljkovic will discuss expanding boundaries to create new generation of therapies that will enhance patient outcomes 7th Annual CAR-TCR Summit September 19-21, 2022, Hynes Convention Center in BostonSeptember 21, 2:00 p.m. ET-Dr. Michael Singer, Chief Scientific Officer, participates in the Leveraging RNA Technology to Change the Face of Clinical Trial Design session. Dr. Singer will discuss how they can be used as treatments beyond oncology due to their predictable pharmacokinetics and enhanced safety.September 21, 3:00 p.m. ET- Dr. Michael Singer, Chief Scientific Officer, participates in the Innovating the Future of Cell Therapy with RNA-Based Approaches panel discussion. AANEM Annual Meeting September 21-24, 2022, Gaylord Opryland Resort & Convention Center in NashvilleSeptember 21, 9:44 a.m. CT-Dr. Volkan Granit, participates in the MGFA session to present data from the phase 2a clinical trial of Descartes-08 in a talk titled ”Phase 1/2A Study of Descartes-08, Autologous mRNA-Engineered Chimeric Antigen Receptor T cells in gMG”. 7th Annual CAR-TCR Summit September 19-21, 2022, Hynes Convention Center in BostonSeptember 19, 9:30 a.m. ET- Dr. Milos Miljkovic, Chief Medical Officer, participates in the Innovations in Gene Engineering & Editing session. Dr. Miljkovic will discuss he pros, cons and applications of key gene editing technologies that are making RNA editing a reality in cell therapy.September 19, 1:30 p.m. ET- Dr Milos Miljkovic, Chief Medical Officer, participates in the Exploring the Advantages & Applications of CAR-T Technology Beyond Oncology workshop to discuss non-oncology indications of CAR-T and how Cartesian has successfully utilized CAR-T therapy for an ongoing Phase 2 clinical trial for Myasthenia Gravis. mRNA Processing Development & Manufacturing Summit September 20-22, 2022, Hilton BostonSeptember 20, 9:00 a.m. ETEmily English, Senior Director, Quality, participates in the “Defining mRNA Drug Substance Quality Control Attributes” worship. Dr. English will discuss the strategies and methods for mRNA quality control and provide a better understanding of quality requirements for process monitoring and lot release of mRNA-based therapeutic products. mRNA-Based Therapeutics Summit July 26-28, 2022, Hilton Boston July 28, 12:00 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in the Unleashing the Power of mRNA Technology for CAR-T Therapies session, a presentation titled “Cell Therapy: In & Beyond Oncology.” Dr. Kurtoglu will discuss cell products engineered with RNA that express Chimeric Antigen Receptor (CAR) being tested in autoimmune disease and frontline oncology indications and the potential of RNA Cell Therapies as there is no limit to the number of cells that can be transfected with multiple RNAs and therapeutic functions. July 28, 4:25 p.m. ET – Dr. Milos Miljkovic, Chief Medical Officer, participates in the Achieving a Successful Route to Equitable Distribution for mRNA-Based Therapeutics & Vaccines session and will lead a presentation titled “Achieving Equitable Access to CAR-T & Other Cellular Therapy Through RNA Engineering.” Dr. Miljkovic will focus on the advantages of RNA-engineered cellular therapy over DNA-based cell therapy. He will also discuss how Cartesian Therapeutics has successfully used three different mRNA-engineered cell therapy products in community clinics around the U.S., and the potential of RNA to make global distribution of effective clinical therapies more equitable. ISSCR Annual Meeting June 15-18, 2022, Moscone West Convention Center in San FranciscoJune 15, 8:30 a.m. PT / 11:30 a.m. ET (available on the virtual meeting platform) – Dr. Murat Kalayoglu, President and Chief Executive Officer, participates as a panelist in Maryland Stem Cell Research Fund Focus Session, “Accelerating Cures – Translating Stem Cell Discoveries into Therapies.” In this Focus session, Maryland-based leaders in the field explore the latest breakthroughs and advances in stem cell disease modeling and tissue engineering approaches. Hear from Dr. Kalayoglu on creating, manufacturing and delivering cell therapies to patients with unmet medical needs. Antibody Engineering & Therapeutics Europe June 9, 2022, Postillion Hotel Amsterdam; Digital Experience: All Sessions Livestreamed June 7 – 9June 9, 2022, 16:55 CET (10:55 a.m. ET) – Dr. Michael Singer presents at Informa’s Antibody Engineering & Therapeutics Conference in a session titled “RNA-Engineered Cell Therapies for Autoimmune Disease.” RNA cell therapies combine the potency of DNA-engineering (such as CAR T-cells) with the speed and manufacturability of RNA. RNA offers another key advantage: controllable pharmacokinetics. In our clinical trials, RNA cell therapies have been remarkably safe. We have administered them in outpatient clinics, with no need for preconditioning chemotherapy. This benefit:risk profile has allowed us to develop therapies for autoimmune disease, including Descartes-08, an anti-BCMA CAR T-cell, for autoantibody-mediated diseases like myasthenia gravis. Maryland Tech Council Industry Awards May 12, 2022, Bethesda North Marriott Hotel & Conference CenterMay 12, 5:30 p.m. ET – Cartesian has been selected as a finalist for the Emerging Life Sciences Company of the Year award for the Maryland Tech Council’s Industry Awards Celebration. The Industry Awards Celebration hosts attendees from the life sciences and technology industries and is Maryland’s largest and most prestigious award ceremony of its kind. 14th MGFA International Conference On Myasthenia And Related Disorders May 10-12, 2022, Hyatt Regency MiamiMay 10, 10:50 a.m. ET – Dr. Volkan Granit, Neurologist at the University of Miami Health System, will present clinical research of Cartesian’s first CAR T-cell therapy for the treatment of generalized myasthenia gravis (GMG). Descartes-08 contains autologous CD8+ T-cells engineered with RNA chimeric antigen receptors (CARs) that bind B-cell maturation antigen (BCMA). BCMA is expressed ubiquitously by plasma cell clones that produce pathogenic autoantibodies. Descartes-08 binds and kills these cells, eliminating the autoantibody source.May 10, 6:00 p.m. ET – Cartesian will present a poster on clinical research from its Phase 1a/2a study for Descartes-08 in patients with generalized Myasthenia Gravis. Patients were treated with increasing doses to determine the safety and preliminary efficacy. Advanced Therapies Week January 25-28, 2022, Miami Beach Convention CenterJan. 27, 2:05 p.m. ET – Dr. Metin Kurtoglu, Chief Operating Officer, participates in a session titled “Delivery Solutions and Alternatives for Gene and Cell Therapy,” with a specific emphasis on RNA Cell Therapy in And Beyond Oncology.Jan. 28, 11:05 a.m. ET – Dr. Emily English, Director of Quality, participates in a session titled “Achieving Best Practice in Quality Control and Assurance,” with a focus on providing an overview of our experience building and evolving quality management systems in an early-stage cell therapy company. 2022 Virtual Advocacy Summit January 20, 20229:00 a.m. ET – Dr. Murat Kalayoglu joins John Stanford, Executive Director at Incubate, in a fireside chat titled “Protecting Innovation: Putting Patients First.” The Maryland Tech Council’s Advocacy Summit will bring industry leaders together to build meaningful relationships with elected officials, provide information about policies that can transform millions of lives and tips on how your advocacy with policymakers in Annapolis can make a difference. Opportunities for Growth: Biotech Land Use Update October 22, 2021Dr. Murat Kalayoglu is joined by other Montgomery County owners and developers, discussing how best to foster the lab space and talent in the area. The discussion focused on nurturing and leveraging the resources of Montgomery County to retain and expand the biotech industry, as well as other growth opportunities in the County. Bio Innovation Conference October 5, 20219:00 a.m. – Dr. Michael Singer participates in a panel titled “Engineered Cell Therapies: Increasingly Complex Product Development.” In this panel, Dr. Singer will explore how Cartesian is developing innovative approaches for novel cell therapeutics for the treatment of a growing list of intractable diseases. The presentation will be followed by a short Q&A session with the panelists.11:00 a.m. – Dr. Murat Kalayoglu moderates a panel titled “Cell and Gene Therapy: Beyond Oncology.” The panel discusses the applications of cell therapy beyond the treatment of advanced cancers. Specific examples include the use of cell & gene therapy for the treatment of autoimmune disorders such as myasthenia gravis, respiratory diseases such as ARDS and COVID-19, and rare genetic disorders such as XMEN disease. Ex-vivo cell modification strategies are compared between different approaches and disease indications. Potential benefits of these novel approaches are weighed against treatment risks and costs. CAR-TCR Summit September 2, 202112:00 p.m. – Dr. Murat Kalayoglu provides a corporate presentation and participates in a Q&A session focused on deploying the company’s RNA Armory® platform to equip cell immunotherapies beyond oncology. He discusses the biological basis and cell therapy engineering approaches to combat respiratory and autoimmune disorders, shares experiences in developing a cGMP manufacturing facility in-house for RNA-based cell therapies, highlights the distinct advantages of an RNA-based engineering platform to targetcells to diseased tissues to deliver any combination of therapies, and provides updates on phase I/II clinical trials for investigational therapies in multiple myeloma, myasthenia gravis, and acute respiratory distress syndrome linked to COVID-19.2:00 p.m. – Dr. Murat Kalayoglu participates in a panel reflecting on historic developments in the industry, and the ‘why’ behind CAR-TCR’s launch into oncology and discussing the relative advantages and challenges of expanding these technologies to indications beyond oncology. Maryland Tech Council Industry Awards Celebration May 20, 2021Cartesian has been selected as a finalist of the “Emerging Life Sciences Company of the Year” and Dr. Murat Kalayoglu has been selected as a finalist for the “Chief Executive Officer of the Year – Life Sciences” by the Maryland Tech Council. The winners of the awards will be announced at the Industry Awards Celebration on May 20. The event celebrates individuals and companies in the government contracting, life sciences and technology industries that have made a significant impact in their respective industry. GEN Panel: Manufacturing CAR-T Therapies March 24, 2021In this panel, Dr. Metin Kurtoglu, Cartesian’s Chief Medical Officer, speaks to Cartesian’s expertise in manufacturing and characterizing the function and potency of CAR-T cell products using its wholly-owned, state-of-the-art GMP manufacturing facility. American Association of Neuromuscular & Electrodiagnostic Medicine Spring Virtual Conference March 2- March 5, 2021Dr. Kelly Gwanthemey, Assistant Prof of Neurology at Virginia Commonwealth University, presents on emerging therapeutics in myasthenia gravis, including Cartesian’s work with an mRNA cell therapy, Descartes-08. Sixth Annual 2020 BioHealth Capital Region Virtual Forum October 19, 2020Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, participated in a panel titled, “Strengths of the Regions – Cutting Edge Therapies.” The panel brought together leaders from three companies to discuss their disruptive pipelines, the strength of the region and challenges brought by the COVID-19 pandemic. “Doing Business in the USA,” Maryland Tech Council, Capital M ZoomCast Live – International Special Edition September 16, 2020Dr. Murat Kalayoglu, President & CEO at Cartesian Therapeutics, joins a panel hosted by Martin Rosendale, CEO of the Maryland Tech Council. On this CapitalM ZoomCast Live event Dr. Kalayoglu discusses Cartesian and its role in the Maryland science eco-system.